By Rebecca Adler, PharmD, BCPS, Clinical Pharmacist. Medically reviewed by Dr. Robert Yamada, MD, Board-Certified Endocrinology.
When Lisa, a 46-year-old marketing director in Charlotte, sat down for a telehealth visit last March, she had a spreadsheet open on her second monitor. Two columns: Saxenda and Zepbound. Monthly cost, injection frequency, expected weight loss percentages pulled from clinical trials, side effects she'd catalogued from Reddit threads and PubMed abstracts. "I told my prescriber I'd done my homework," she said. "He looked at my screen and said, 'You've done a lot of homework. Now let me tell you what the spreadsheet won't show you.'" She'd lost 14 pounds on Saxenda over four months but plateaued. Her prescriber recommended switching to tirzepatide. Eight months later, she's down another 31 pounds. Her A1c dropped from 6.3 to 5.4.
Lisa's experience is one data point. But her question, Saxenda or Zepbound, is one that roughly 2,900 people type into Google every month. And the answer is genuinely more complicated than "pick the one with bigger trial numbers."
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Long-Term & Maintenance hub.
The Drugs Are Fundamentally Different
Start here, because this matters more than branding. Saxenda is liraglutide, a GLP-1 receptor agonist dosed daily via subcutaneous injection. Zepbound is tirzepatide, a dual GIP and GLP-1 receptor agonist dosed weekly.
That "dual" part is the headline difference. Tirzepatide hits two incretin receptors instead of one. Whether the GIP component is doing heavy independent lifting or mostly amplifying the GLP-1 signal is still being worked out in mechanistic research, but the clinical results are hard to argue with.
Here's the thing: Saxenda was the earlier entrant for obesity. It got its FDA approval in 2014. Zepbound arrived in 2023. A decade of pharmaceutical development separates them, and the newer drug reflects that gap.
Key facts at a glance:
- Saxenda (liraglutide): GLP-1 agonist, daily injection, FDA-approved for chronic weight management
- Zepbound (tirzepatide): dual GIP/GLP-1 agonist, weekly injection, FDA-approved for chronic weight management
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications.
What the Trials Actually Show
We don't have a direct head-to-head trial comparing Saxenda (liraglutide) to Zepbound (tirzepatide) for obesity. What we do have is SURPASS-2, which compared tirzepatide against semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Tirzepatide produced greater reductions in both weight and A1c across all dose arms.
For obesity-specific data, you're comparing across trial programs: SURMOUNT (tirzepatide) versus SCALE (liraglutide). That's indirect comparison, which means you're looking through foggy glass. Different patient populations, different trial designs, different lifestyle intervention protocols. Still, the direction is consistent: tirzepatide produces larger average weight reductions.
But trial averages are strange creatures. They compress enormous individual variation into a single number. SURMOUNT-1 reported substantial spread within the same dose arm, which is the normal pattern in GLP-1 research. Some patients on the highest tirzepatide dose lost over 25% of body weight. Others on the same dose lost under 10%. The average landed around 22.5% at 72 weeks. That average is real, but it's not a promise.
The boring truth is that individual response varies enough that picking between these two drugs based solely on trial averages is like choosing a restaurant based on its Yelp rating without reading any of the actual reviews.
How Pricing and Access Shape the Decision
If insurance covers one and not the other, that often ends the discussion before pharmacology enters the room.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Brand manufacturers (Eli Lilly for Zepbound, Novo Nordisk for Saxenda) set list prices. Your out-of-pocket cost depends entirely on your coverage. Manufacturer savings programs exist for commercially insured patients but typically exclude Medicare, Medicaid, and other government-funded plans.
Compounding pharmacies offer a different path. These are state-licensed pharmacies operating under USP 795 (non-sterile) and USP 797 (sterile) standards, preparing personalized medications under individual prescriptions. Compounded tirzepatide is dispensed cash-pay when a licensed prescriber determines a compounded formulation is clinically appropriate. It is not FDA-reviewed.
Telehealth platforms sit between these models, connecting patients with licensed prescribers who may route prescriptions to brand-name pharmacies, compounding pharmacies, or both. The quality gap between platforms is wide. Good evaluation criteria: prescriber licensure in your state, documented intake capturing full medical history and contraindications, transparent pricing, clear pharmacy sourcing, and accessible follow-up channels.
If any of those answers require digging or feel evasive, that's signal in its own right.
The Switching Question
Switching from Saxenda to Zepbound (or to compounded tirzepatide) is a routine clinical move. Lisa's story above is a common pattern: partial response on one agent, better response on another.
The protocol is straightforward. You don't try to find a "dose equivalent" and jump across. The new agent starts at its lowest dose and titrates up. Your body needs to acclimate to a different molecule, and the GI side effects of starting too high are nobody's idea of a good time.
Worth knowing: both agents share the GLP-1 class side-effect profile (nausea, constipation, diarrhea, injection site reactions) and class warnings (pancreatitis risk, thyroid C-cell tumor risk in animal models, gallbladder events). Differences in tolerability between them tend to be modest at the individual level, but they're real enough that some patients tolerate one much better than the other.
Overlooked Factors That Actually Move the Needle
Every published GLP-1 weight-loss trial, SURMOUNT-1, STEP 1, the SURPASS series, included a lifestyle component. Calorie guidance. Physical activity recommendations. The published numbers reflect medication plus lifestyle, not medication alone.
Practical translation: the drug isn't the whole plan. Patients who treat GLP-1 therapy as one input among several tend to land closer to those trial averages. Four inputs that are consistently underweighted in real-world practice:
- Protein intake (most patients undershoot by a wide margin on GLP-1s because appetite drops)
- Resistance training (preserving lean mass during rapid weight loss isn't optional, it's structural)
- Sleep quality (poor sleep disrupts hunger hormones in ways that partially counteract the medication)
- Hydration (dehydration mimics and worsens GI side effects)
Each is a small behavioral lift. Over months, they compound into measurably different outcomes.
And here's a habit that sounds trivial but consistently separates high-outcome patients from the rest: keeping a short weekly log. Dose, side effects, hydration, one subjective wellbeing note. Patients who bring that log to follow-up visits get dramatically more productive appointments. "I noticed mild reflux on injection-day evenings for the past two weeks; I tried elevating my head and it partially helped" gives a prescriber something to work with. "Is reflux normal?" does not.
Refill Gaps and Storage: the Mundane Stuff That Matters
Refill cadence is the second most-cited reason patients fall off GLP-1 therapy, right behind side-effect intolerance. Put the refill on a recurring calendar reminder. This prevents most avoidable gaps.
Storage is another quiet saboteur. A vial that spent three days in a 105-degree UPS truck, or got frozen during winter shipping, should not be assumed to retain full potency. Call the pharmacy if you have any doubt. This applies to both brand and compounded products.
What Changes Year to Year
Coverage decisions, manufacturer supply, FDA shortage status, regulatory guidance: all of these shift on a timeline measured in months, not years. The answer that's accurate in June may be outdated by October. Confirm specifics with your prescriber and pharmacy at every fill.
Recent trends include broadening insurance coverage for obesity-indicated GLP-1 medications, evolving cardiovascular outcome evidence (the SELECT trial for semaglutide showed cardiovascular benefit independent of diabetes status), and ongoing investigation of additional incretin-targeted agents for obesity.
My genuinely opinionated take: within two years, the Saxenda-vs-Zepbound question will feel like asking whether you should get a flip phone or a smartphone. Liraglutide did important pioneering work, but the newer dual-agonist approach is producing better outcomes for most patients, and the field is moving in that direction. That doesn't make Saxenda wrong for every patient today, but the trajectory is clear.
Frequently Asked Questions
Should I discuss this with a clinician before deciding?
Yes. Any question affecting how a prescription medication is selected, dosed, or administered belongs in a clinical conversation. This article provides general education, not individualized guidance.
Which option produces more weight loss on average?
In SURPASS-2, tirzepatide produced greater weight reduction than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Indirect comparisons for obesity indications also tend to favor tirzepatide. But individual response varies substantially, and trial-by-trial comparisons have real limitations.
Is one option safer than the other?
Both share the GLP-1 class side-effect profile and warnings. Tolerability differences between agents exist but are typically modest at the patient level. Your prescriber will weigh your specific comorbidities and contraindications.
Can I switch from Saxenda to Zepbound?
Yes. Switching is a routine clinical decision. The new agent is started at its lowest dose and re-titrated upward rather than jumping to a presumed dose equivalent.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. They are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a compounded formulation is clinically appropriate.
How often is Saxenda injected versus Zepbound?
Saxenda requires daily subcutaneous injection. Zepbound is a once-weekly injection. For many patients, this difference alone is a significant quality-of-life factor.
What's the strongest predictor of long-term success on either medication?
Across the GLP-1 class, the strongest predictor of long-horizon outcome is sustained months on therapy at or near the maintenance dose. Not starting dose, not which specific molecule, not which brand. Time at therapeutic dose. Everything else matters less.
Continue the Series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About This Article
Written by Rebecca Adler, PharmD, BCPS (Clinical Pharmacist). Medically reviewed by Dr. Robert Yamada, MD (Board-Certified Endocrinology). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.